Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone

Bruna Tedeschi, Gian Luigi Spadoni, Maria Lucia Sanna, Patrizia Vernole, Daniela Caporossi, Stefano Cianfarani, Benedetto Nicoletti, Brunetto Boscherini

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A few years ago it was reported that some growth-hormone-deficient children had developed leukemia following therapy with human growth hormone. This raised concern that this therapy may stimulate tumor development. Since it is known that the tendency to develop cancer is closely related to chromosome breakage, we decided to investigate whether recombinant human growth hormone (rhGH) therapy can increase chromosome fragility. Ten short normal children were studied during their first year of treatment. Lymphocytes were collected at 0, 6 and 12 months of rhGH therapy, and we assessed the rate of spontaneous chromosome aberrations, the frequency of sister chromatid exchanges, the proliferative rate indices, the expression of common fragile sites induced by aphidicolin, and the sensitivity towards the radiomimetic action of bleomycin. At 6 months of therapy, there was a significant increase in bleomycin-induced chromosome aberrations, which remained unchanged after 1 year of treatment. An increase in spontaneous chromosome rearrangements at 6 and 12 months of therapy was also observed. These findings are further supported by data obtained from the analysis of 16 short normal children already on rhGH therapy.

Original languageEnglish
Pages (from-to)459-463
Number of pages5
JournalHuman Genetics
Volume91
Issue number5
DOIs
Publication statusPublished - Jun 1993

Fingerprint

Chromosome Fragility
Human Growth Hormone
Growth Hormone
Lymphocytes
Therapeutics
Chromosome Aberrations
Aphidicolin
Chromosome Breakage
Sister Chromatid Exchange
Bleomycin
Neoplasms
Leukemia
Chromosomes

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone. / Tedeschi, Bruna; Spadoni, Gian Luigi; Sanna, Maria Lucia; Vernole, Patrizia; Caporossi, Daniela; Cianfarani, Stefano; Nicoletti, Benedetto; Boscherini, Brunetto.

In: Human Genetics, Vol. 91, No. 5, 06.1993, p. 459-463.

Research output: Contribution to journalArticle

Tedeschi, B, Spadoni, GL, Sanna, ML, Vernole, P, Caporossi, D, Cianfarani, S, Nicoletti, B & Boscherini, B 1993, 'Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone', Human Genetics, vol. 91, no. 5, pp. 459-463. https://doi.org/10.1007/BF00217772
Tedeschi, Bruna ; Spadoni, Gian Luigi ; Sanna, Maria Lucia ; Vernole, Patrizia ; Caporossi, Daniela ; Cianfarani, Stefano ; Nicoletti, Benedetto ; Boscherini, Brunetto. / Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone. In: Human Genetics. 1993 ; Vol. 91, No. 5. pp. 459-463.
@article{ed19075e3ca34a9cb5b45d5922273e7e,
title = "Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone",
abstract = "A few years ago it was reported that some growth-hormone-deficient children had developed leukemia following therapy with human growth hormone. This raised concern that this therapy may stimulate tumor development. Since it is known that the tendency to develop cancer is closely related to chromosome breakage, we decided to investigate whether recombinant human growth hormone (rhGH) therapy can increase chromosome fragility. Ten short normal children were studied during their first year of treatment. Lymphocytes were collected at 0, 6 and 12 months of rhGH therapy, and we assessed the rate of spontaneous chromosome aberrations, the frequency of sister chromatid exchanges, the proliferative rate indices, the expression of common fragile sites induced by aphidicolin, and the sensitivity towards the radiomimetic action of bleomycin. At 6 months of therapy, there was a significant increase in bleomycin-induced chromosome aberrations, which remained unchanged after 1 year of treatment. An increase in spontaneous chromosome rearrangements at 6 and 12 months of therapy was also observed. These findings are further supported by data obtained from the analysis of 16 short normal children already on rhGH therapy.",
author = "Bruna Tedeschi and Spadoni, {Gian Luigi} and Sanna, {Maria Lucia} and Patrizia Vernole and Daniela Caporossi and Stefano Cianfarani and Benedetto Nicoletti and Brunetto Boscherini",
year = "1993",
month = "6",
doi = "10.1007/BF00217772",
language = "English",
volume = "91",
pages = "459--463",
journal = "Human Genetics",
issn = "0340-6717",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone

AU - Tedeschi, Bruna

AU - Spadoni, Gian Luigi

AU - Sanna, Maria Lucia

AU - Vernole, Patrizia

AU - Caporossi, Daniela

AU - Cianfarani, Stefano

AU - Nicoletti, Benedetto

AU - Boscherini, Brunetto

PY - 1993/6

Y1 - 1993/6

N2 - A few years ago it was reported that some growth-hormone-deficient children had developed leukemia following therapy with human growth hormone. This raised concern that this therapy may stimulate tumor development. Since it is known that the tendency to develop cancer is closely related to chromosome breakage, we decided to investigate whether recombinant human growth hormone (rhGH) therapy can increase chromosome fragility. Ten short normal children were studied during their first year of treatment. Lymphocytes were collected at 0, 6 and 12 months of rhGH therapy, and we assessed the rate of spontaneous chromosome aberrations, the frequency of sister chromatid exchanges, the proliferative rate indices, the expression of common fragile sites induced by aphidicolin, and the sensitivity towards the radiomimetic action of bleomycin. At 6 months of therapy, there was a significant increase in bleomycin-induced chromosome aberrations, which remained unchanged after 1 year of treatment. An increase in spontaneous chromosome rearrangements at 6 and 12 months of therapy was also observed. These findings are further supported by data obtained from the analysis of 16 short normal children already on rhGH therapy.

AB - A few years ago it was reported that some growth-hormone-deficient children had developed leukemia following therapy with human growth hormone. This raised concern that this therapy may stimulate tumor development. Since it is known that the tendency to develop cancer is closely related to chromosome breakage, we decided to investigate whether recombinant human growth hormone (rhGH) therapy can increase chromosome fragility. Ten short normal children were studied during their first year of treatment. Lymphocytes were collected at 0, 6 and 12 months of rhGH therapy, and we assessed the rate of spontaneous chromosome aberrations, the frequency of sister chromatid exchanges, the proliferative rate indices, the expression of common fragile sites induced by aphidicolin, and the sensitivity towards the radiomimetic action of bleomycin. At 6 months of therapy, there was a significant increase in bleomycin-induced chromosome aberrations, which remained unchanged after 1 year of treatment. An increase in spontaneous chromosome rearrangements at 6 and 12 months of therapy was also observed. These findings are further supported by data obtained from the analysis of 16 short normal children already on rhGH therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027290697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027290697&partnerID=8YFLogxK

U2 - 10.1007/BF00217772

DO - 10.1007/BF00217772

M3 - Article

VL - 91

SP - 459

EP - 463

JO - Human Genetics

JF - Human Genetics

SN - 0340-6717

IS - 5

ER -